A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates
Abstract Non-alcoholic steatohepatitis (NASH) is a progressive and severe liver disease, characterized by lipid accumulation, inflammation, and downstream fibrosis. Despite its increasing prevalence, there is no approved treatment yet available for patients. This has been at least partially due to t...
Guardado en:
Autores principales: | Simon Ströbel, Radina Kostadinova, Katia Fiaschetti-Egli, Jana Rupp, Manuela Bieri, Agnieszka Pawlowska, Donna Busler, Thomas Hofstetter, Katarzyna Sanchez, Sue Grepper, Eva Thoma |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f68ec732dd9c4e5cbe369ca6c1215b3e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Statins in Non-alcoholic Steatohepatitis
por: Jose D. Torres-Peña, et al.
Publicado: (2021) -
Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment
por: Chengyuan Liang, et al.
Publicado: (2021) -
Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates
por: Philippe Garteiser, et al.
Publicado: (2021) -
Bile acids contribute to the development of non-alcoholic steatohepatitis in mice
por: Justine Gillard, et al.
Publicado: (2022) -
Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mice
por: Joost Willebrords, et al.
Publicado: (2017)